drugset / Trial / NCT06964971
Treatment of Transfusion-dependent Nonsevere Aplastic Anemia With Luspatercept: a Multicenter Prospective Clinical Study
Non-randomizedParallel-groupOpen-labelTreatment
Summary
The goal of this clinical trial is to learn whether Luspatercept alone or in combination with Deferasirox can promote hematopoietic function in patients with transfusion-dependent non-severe aplastic anemia, as well as to assess the safety and efficacy of this treatment approach. The main questions it aims to answer is: whether the combination therapy of Luspatercept and Deferasirox can improve hemoglobin levels in these patients. Participants will receive Luspatercept every 3 to 5 weeks based on hemoglobin response, undergo complete blood counts every 1 to 3 weeks, and receive other necessary evaluations as required.
Timeline
- Start
- 2025-05-20
- Primary completion
- 2027-05-20
- Completion
- 2027-06-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Deferasirox | Unknown | 8 mg/kg | Oral |
| Subject | Deferasirox | Unknown | 10 mg/kg | Oral |
| Subject | Deferasirox | Unknown | 20 mg/kg | Oral |
| Subject | Luspatercept | Protein / enzyme biologic | 1.5 mg/kg | Subcutaneous |